ArticlemedRxiv : the preprint server for health sciences2025
The spectrum of Alzheimer's disease.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
While hippocampal (H) and inferior parietal lobule (IPL) atrophy are used routinely in Alzheimer's disease (AD) diagnostics, the role of enlarged choroid plexus (ChP) remains unclear. We here examined the AD Neuroimaging Initiative (ADNI) cohort (N=872) to investigate the contribution of enlarged ChP in predicting AD using MRI volumetry. Analyses revealed that no individual volumetric brain changes, nor their combination, can predict AD. Among AD patients, only ~ 19%, 12% and 5% exhibited changes in H, ChP or IPL volumes, while 45% showed no volumetric brain changes at all, not even longitudinally. Amyloid-b peptides, therefore, contribute to brain atrophy and neuronal loss at best only in a subset of amyloid PET-CT positive AD patients. These findings suggest that despite shared amyloidopathy, the observed brain volumetric phenotypes, together with their corresponding cognitive and CSF biomarker profiles, represent unique entities within the AD spectrum much like the synucleinopathies, tauopathies and TDP43-proteinopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.